Table 3.

Prevalence of HBV-DNA positivity according to demographic and biochemical variables among diabetic patients

	No. of all diabetic participants (%): 733 (100%)	No. of HBV DNA negative subjects (%): 714 (97.4%)	No. of HBV DNA positive subjects (%): 19 (2.6%)	Adjusted OR (95% CI)	P-value
Age groups (years)
26–30	16 (2.2%)	16 (100.0%)	0 (0.0%)	1.0
31–40	67 (9.1%)	67 (100.0%)	0 (0.0%)	0.00	0.99
41–50	143 (19.5%)	137 (95.8%)	6 (4.2%)	0.00	0.99
51–60	284 (38.7%)	281 (98.9%)	3 (1.1%)	0.24 (0.06–0.99)	0.05
61–70	147 (20.1%)	141 (95.9%)	6 (4.1%)	3.99 (0.98–16.2)	0.05
≥ 71	76 (10.4%)	72 (94.7%)	4 (5.3%)	1.31 (0.36–4.77)	0.69
Gender
Male	256 (34.9%)	252 (98.4%)	4 (1.6%)	1.0
Female	477 (65.1%)	462 (96.9%)	15 (3.1%)	2.045 (0.67–6.23)	0.208
FBS (mg/dL)
≤ 115	128 (17.5%)	124 (96.9%)	4 (3.1%)	1.0
116–125	89 (12.1%)	87 (97.8%)	2 (2.2%)	0.8 (0.26–2.50)	0.7
≥ 126	516 (70.4%)	503 (97.5%)	13 (2.5%)	1.12 (0.25–5.07)	0.88
Cholesterol (mg/dL)
≤ 200	403 (55.0%)	391 (97.0%)	12 (3.0%)	0.69 (0.19–2.49)	0.57
201–240	186 (25.4%)	182 (97.8%)	4 (2.2%)	0.97 (0.213–4.39)	0.96
≥ 241	144 (19.6%)	141 (97.9%)	3 (2.1%)	1.0
TG (mg/dL)
≤ 150	228 (31.1%)	219 (96.0%)	9 (4.0%)	1.0
151–200	239 (32.6%)	232 (97.1%)	7 (2.9%)	0.278 (0.1–1.04)	0.06
≥ 201	266 (36.3%)	263 (98.9%)	3 (1.1%)	0.378 (0.1–1.48)	0.16
ALT levels (IU/L)
≤ 24	324 (44.2%)	318 (98.1%)	6 (1.9%)	1.0
25–40	256 (34.9%)	248 (96.9%)	8 (3.1%)	1.71 (0.59–4.99)	0.33
41–80	130 (17.7%)	128 (98.5%)	2 (1.5%)	0.48 (0.10–2.31)	0.36
≥ 81	23 (3.1%)	20 (87.0%)	3 (13.0%)	9.60 (1.51–61.07)	0.02
AST levels (IU/L)
≤ 24	464 (63.3%)	453 (97.6%)	11 (2.4%)	1.0
25–40	187 (25.5%)	182 (97.3%)	5 (2.7%)	0.88 (0.31–2.58)	0.82
41–80	78 (10.6%)	75 (96.2%)	3 (3.8%)	0.61 (0.34–2.23)	0.45
≥ 81	4 (0.5%)	4 (100.0%)	0 (0.00%)	0.00	0.99

HBV hepatitis B virus; FBS fasting blood sugar; TG triglyceride; ALT alanine aminotransferase; AST aspartate aminotransferase; OR odds ratio; CI confidence interval